Summary
The influence of the acute and chronic administration of antihypertensive agents on blood flow to various organs which are known targets of hypertension is important in the determination of drug therapy for this disorder.
In association with the frequently observed fall in cardiac output and increase in total peripheral resistance in response to acute administration, β-blockers may induce a decrease in blood flow to the brain and kidney. However, during chronic treatment it has been widely shown that total peripheral resistance returns to pretreatment levels (except for labetalol, a β-blocker with α-blocking properties) whilst renal and cerebral blood flows are unaffected. Although α-blockers acutely lower blood pressure and induce a baroreflex-mediated increase in heart rate and cardiac output while not affecting cerebral blood flow, during chronic treatment no change in systemic or cerebral or renal blood flow is observed. Diuretics and dietary sodium restriction, which are the most widely used therapeutic interventions, are usually well tolerated; however, in aged patients in whom renal adaptation to sodium depletion is impaired, deterioration of renal function may be observed.
Similar content being viewed by others
References
Anderson S, Brenner BM. Effect of aging on the renal glomerulus. American Journal of Medicine 80: 435–442, 1986
Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. Journal of Clinical Investigation 77: 1993–2000, 1986
Barry DI, Lassen NA. Cerebral blood flow autoregulation in hypertension and effects of antihypertensive drugs. Journal of Hypertension 2 (Suppl. 3): S519–S526, 1984
Bauer JH. Effects of propranolol therapy on renal function and body fluid composition. Archives of Internal Medicine 143: 927–931, 1983
Bauer JH, Jones LB, Gaddy P. Effects of prazpsin therapy on BP, renal function, and body fluid composition. Archives of Internal Medicine 144: 1196–1200, 1984
Bertel O, Conen LD. Treatment of hypertensive emergencies with the calcium channel blocker nifedipine. American Journal of Medicine 79(4A): 31–35, 1985
Bertel O, Marx BE. Effects of antihypertensive treatment on cerebral perfusion. American Journal of Medicine 82 (Suppl. 3B): 29–36, 1987
Bloomfield RL, Stump DA, Graves JW, Wagoner SH, Hinshel-wood LC, et al. Arterial blood pressure and cerebral blood flow responses to carbon dioxide inhalation before and after treatment of essential hypertension. Journal of Hypertension 4 (Suppl. 5): S474–S476, 1986
Britton KE, Nawaz CC, Mlodkowska NE, Carroll M, Horne T, et al. Total and intrarenal flow distribution in healthy subjects: technique, acute effects of ibopamine and of indoramin. Nephron 43: 265–273, 1986
de Carvalho JGR, Dunn FG, Lohmoller G, Frohlich ED. Hemodynamic correlates of prolonged thiazide therapy: comparison of responders and nonresponders. Clinical Pharmacology and Therapeutics 22: 875–880, 1977
Falch DK, Paulsen AQ, Odegaard AE, Norman N. Central and renal circulation, electrolyte, body weight and renin during atenolol treatment in essential hypertension. Current Therapeutic Research 26: 813–820, 1979
Gensini G, Dator C, Esente P, Caruso FS, Solomon T. Comparison of the acute hemodynamic effects of intravenous celiprolol and propranolol in patients with suspected coronary disease. Journal of Cardiovascular Pharmacology 8 (Suppl. 4): S83–S85, 1986
Ghose RR, Mathur YB, Upadhyay M, Morgan WD, Khan S, Treatment of hypertensive emergencies with oral labetalol. British Medical Journal 2: 96–97, 1978
Greene AM, Boltax AJ, Scherr ES. Acute effects of intravenous chlorothiazide upon cardiovascular hemodynamics. American Heart Journal 62: 659–664, 1961
Griffith DNW, James IM, Newbury PA, Woollard ML. The effect of beta-adrenergic receptor blocking drugs on cerebral blood flow. British Journal of Clinical Pharmacology 7: 491–494, 1979
Grimm M, Weidmann P, Meier A, Keusch G, Ziegler W, et al. Correction of altered noradrenaline reactivity in essential hypertension by indapamide. British Heart Journal 46: 404–409, 1981
Hares P, James IM, Griffith D. The effect of acebutolol on the cerebral circulation of man. British Journal of Clinical Pharmacology 4: 373–375, 1977
Hollenberg NK, Adams DF, Solomon HS, Rashid A, Abrams W, et al. Senescence and the renal vasculature in normal male. Circulation Research 34: 309–316, 1974
Hollenberg NK, Adams DF, McKinstry DN, Williams GH, Borucki LJ, et al. Beta-adrenoreceptor-blocking agents and the kidney: effect of nadolol and propranolol on the renal circulation. British Journal of Clinical Pharmacology 7 (Suppl. 2): S219–S225, 1979
Hricik DE, Browning PJ, Kopelman RK, Gorno WE, Madias NE, et al. Captopril-indueed functional renal insufficiency in patients with bilateral renal artery stenosis or stenosis of a solitary kidney. New England Journal of Medicine 308: 373–376, 1983
Hulse JA, Taylor DSI, Dillon MJ. Blindness and paraplegia in severe childhood hypertension. Lancet 2: 553–556, 1979
Ingram DM, House AK, Thompson GH, Stacey MC, Castelden WM, et al. Beta-adrenergic blockade and peripheral disease. Medical Journal of Australia 1: 509–511,1982
Kern MJ, Ganz P, Horowitz JD, Gaspar J, Barry WH, et al. Potentiation of coronary vasoconstriction by beta-adrenergic blockade. Circulation 67: 1178–1183, 1983
Kobrin I, Messerli FH, Amodeo C, Ventura HO, Frohlich ED. Immediate hemodynamic effects of urapidil in patients with essential hypertension. American Journal of Cardiology 55: 722–725, 1985
Ledingham JGG, Rajagopalam B. Cerebral complications in the treatment of malignant hypertension. Quarterly Journal of Medicine 48: 25–35, 1979
Levenson J, Simon AC, Bouthier JD, Benetos A, Safar ME. Post-synaptic alpha-blockade and brachial artery compliance in essential hypertension. Journal of Hypertension 2: 37–41, 1984
London GM, Safar ME, Levenson JA, Simon AC, Temmar MA. Renal filtration, effective vascular compliance and partition of fluid volumes in sustained essential hypertension. Kidney International 20: 97–103, 1981
Lund-Johansen P. Hemodynamic consequences of long-term beta-blocker therapy: a 5-year follow up study of atenolol. Journal of Cardiovascular Pharmacology 1: 487–495, 1979
Lund-Johansen P. Short-term and long-term (six years) hemodynamic effects of labetalol in essential hypertension. American Journal of Medicine 75(4A): 24–31, 1983
Magrini F, Shimizu M, Roberts N, Fouad FM, Tarazi RC, et al. Converting enzyme inhibition and coronary blood flow. Circulation 75 (Suppl. 1): 168–174, 1987
Man in’t Veld A, Van den Meiracker A, Schalekamp Madh. The effect of beta-blockers on total peripheral resistance. Journal of Cardiovascular Pharmacology 8 (Suppl. 4): S49–S60, 1986
Mimran A, Jover B, Casellas D. Renal adaptation to sodium deprivation. American Journal of Medicine 76(5B): 14–21, 1984
Mitchell HC, Graham RM, Pettinger WA. Renal function during long-term treatment of hypertension with minoxidil. Annals of Internal Medicine 93: 676–681, 1980
Mourad G, Mimran A, Mion CM. Recovery of renal function in patients with malignant nephrosclerosis on maintenance dialysis with management of blood pressure by captopril. Nephron 41: 166–169, 1985
Mulvihill-Wilson J, Gaffney FA, Pettinger WA, Blomqvist CG, Anderson S, et al. Hemodynamic and neuroendocrine responses to acute and chronic alpha-adrenergic blockade with prazosin and phenoxybenzamine. Circulation 67: 383–393, 1983
Narins RG. The development and progression of chronic renal disease: can it be prevented or attenuated? Drugs 35 (Suppl. 6) 78–82, 1988
O’Connor DT. Response of the renal kallikrein-kinin system, intravascular volume, and renal hemodynamics to sodium restriction and diuretic treatment in essential hypertension. Hypertension 4 (Suppl. 3): 72–78, 1982
O’Connor DT, Preston RA. Urinary kallikrein activity, renal hemodynamics, and electrolyte handling during chronic beta blockade with propranolol in hypertension. Hypertension 4: 742–749, 1982
O’Connor DT, Preston RA, Mitas JA, Frigon RP, Stone RA. Urinary kallikrein activity and renal vascular resistance in the antihypertensive response to thiazide diuretics. Hypertension 3: 139–147, 1981
O’Connor DT, Mosley CA, Cervenka J, Bernstein KN. Contrast-ing renal haemodynamic responses to the angiotensin converting enzyme inhibitor enalapril and the beta-adrenergic antagonist metoprolol in essential hypertension. Journal of Hypertension 2 (Suppl. 2): 89–92, 1984
Pedersen EB. Glomerular filtration rate and renal plasma flow in patients with essential hypertension before and after treatment with alprenolol. Acta Medica Scandinavica 198: 365–371, 1975
Pruss TP, Khandwala A, Wolf PS, Grebow P, Wong L. Celiproiol: a new beta-adrenoceptor antagonist with novel ancillary properties. Journal of Cardiovascular Pharmacology 8 (Suppl. 4): S29–S32, 1986
Ram CVS, Meese R, Kaplan NM, Devous MD, Bonte FJ, et al. Antihypertensive therapy in the elderly. American Journal of Medicine 82(1A): 53–57, 1987
Riddell JG, Shanks RG, Brogden RN. Celiprolol: A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. Drugs 34: 438–458, 1987
Rouleau JL, Chatterjee K, Benge W, Parmley W, Hiramatsu B. Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischémic heart failure: a comparative study. Circulation 65: 671–678, 1982
Schoetensack W, Bruckschen EG, Zech K. Urapidil. In Scriabine (Ed.) New drugs annual: cardiovascular drugs, pp. 19–48, Raven Press, New York, 1983
Smith RS, Warren DJ. Effect beta-blocking drugs on peripheral blood flow in intermittent claudication. Journal of Cardiovascular Pharmacology 4: 2–4, 1982
Strandgaard S. Autoregulation of cerebral blood flow in hypertensive patients. Circulation 53: 720–727, 1976
Sullivan JM, Adams DF, Hollenberg NK. Beta-adrenergic blockade in essential hypertension. Circulation Research 39: 532–535, 1976
Svensson A, Gudbransson T, Sivertsson R, Hansson L. Haemo-dynamic effects of metoprolol and pindolol in hypertensive patients. British Journal of Pharmacology 13 (Suppl. 2): S259–S267, 1982
Tarazi RC, Dustan HP. Beta adrenergic blockade in hypertension. American Journal of Cardiology 29: 633–640, 1972
Textor SC, Fouad FM, Bravo EL, Tarazi RC, Vidt DG, et al. Redistribution of cardiac output to the kidneys during oral nadolol administration. New England Journal of Medicine 307: 601–605, 1982
Traub YM, Shapiro AP, Dunjovny M, Nelson D. Cerebral blood flow changes with diuretic therapy in elderly subjects with systolic hypertension. Clinical and Experimental Hypertension 4A: 1193–1201, 1982
Vaughan ED, Carey RM, Peach MJ, Ackerly JA, Ayers CR. The renin response to diuretic therapy. Circulation Research 42: 376–381, 1978
Warren DJ, Swainson CP, Wright N. Deterioration of renal function after beta-blockade in patients with chronic renal failure and hypertension. British Medical Journal 2: 193–194, 1974
Weber MA, Drayer JIM, Rev A, Laragh JH. Disparate patterns of aldosterone response during diuretic treatment of hyperten-sion. Annals of Internal Medicine 87: 558–563, 1977
Weidmann P, Gnadinger MP, Ziswiler HR, Shaw S, Bachmann C, et al. Cardiovascular, endocrine and renal effects of atrial natriuretic peptide in essential hypertension. Journal of Hypertension 4 (Suppl. 2): S71–S83, 1986
Ying CY, Tifft CP, Gavras H, Chobanian AV. Renal revascularization in the azotemic hypertensive patient resistant to therapy. New England Journal of Medicine 311: 1070–1075, 1984
Zech P, Pozet N, Labeeuw M, Sassard J, Bernheim J, et al. Acute renal effects of new beta adrenergic receptor site blocking agents on renal function. Proceedings of the European Dialysis and Transplant Association 12: 203–208, 1976
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mimran, A., Ducailar, G. Systemic and Regional Haemodynamic Profile of Diuretics and α- and β-Blockers. Drugs 35 (Suppl 6), 60–69 (1988). https://doi.org/10.2165/00003495-198800356-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198800356-00008